First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

PIK3CA mutations are highly prevalent in solid tumors. Targeting phosphatidylinositol 3-kinase α is therefore an attractive strategy for treating cancers harboring PIK3CA mutations. Here, we report the results from a phase Ia, open label, dose-escalation and -expansion study (NCT03544905) of CYH33,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao-Li, Liu, Fu-Rong, Liu, Ji-Hong, Zhao, Hong-Yun, Zhang, Yang, Wang, Zhi-Qiang, Qiu, Miao-Zhen, Xu, Fei, Yu, Qiu-Qiong, Du, Yi-Wu, Shi, Yan-Xia, Wang, De-Sheng, Wang, Feng-Hua, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669016/
https://www.ncbi.nlm.nih.gov/pubmed/36385120
http://dx.doi.org/10.1038/s41467-022-34782-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669016/
https://www.ncbi.nlm.nih.gov/pubmed/36385120
http://dx.doi.org/10.1038/s41467-022-34782-9

Ejemplares similares